November 11, 2017
Few can make a stronger case for the health of Digital Health then Robert Mittendorff, MD, partner at Norwest Venture Partners, co-chair of the Digital Healthcare Innovation Summit, and emergency room physician.
In this Breaking Health podcast, Dr. Mittendorff points to the strength of portfolio company iRhythm, which sports a market cap over $1 billion as evidence of the potential for strong outcomes in Digital Health investments.
He also explains how that success is influencing his vetting process as he reviews new deals and identifies those areas that intrigue him the most including IT companies that serve pharma, genomics companies that can aid in diagnosis, and companies that employ artificial intelligence effectively.
Dr. Mittendorff credits the FDA and its new commissioner, Scott Gottlieb, MD, for introducing “the most well thought out approach to Digital Health we have seen.”
Finally, he sees an enormous future in companies like VisitPay that will help patients manage payments for the healthcare they need.
Go to the website for DHIS to view the agenda and to register to attend the Digital Healthcare Innovation Summit. Use the code mentioned in the podcast to save on the registration costs.
Robert Mittendorff, MD, MBA
Norwest Venture Partners
Robert Mittendorff brings to Norwest Venture Partners more than a decade of operational and medical experience. Based in Norwest’s Palo Alto office, Robert focuses on investing capital in venture and growth opportunities in the healthcare sector, including digital health and healthcare IT, technology enabled healthcare services, medical devices, diagnostics, and specialty pharma. He currently serves on the board of iCardiac, and is a board observer at Crossover Health, iRhythm, and Telcare, and was involved with the initial investments in Misfit Wearables and Health Catalyst. He has also been involved in Norwest’s follow-on investment in Basis (acquired by Intel). Robert was a previous board observer at Intersect ENT (Nasdaq: XENT).
Prior to Norwest, Robert was the Vice President of Marketing and Business Development at Hansen Medical Inc. (Nasdaq: HNSN). During his tenure, he launched multiple products, including the Magellan and Sensei X robotic systems, and was involved in leading products from concept to first commercial shipment. As a corporate officer, Robert also led the Company’s partnerships with GE, Siemens, Philips and St. Jude Medical and executed transactions totaling over $100M. He created the Scientific Advisory Board and participated in two public financings.
Prior to Hansen Medical, Robert worked in the device, pharmaceutical and biotech industries with experience at a number of companies, working in strategic, business development and marketing capacities.
Robert is also a board certified emergency physician who completed his residency training at Stanford. Robert received his M.D. from Harvard Medical School and his M.B.A. from Harvard Business School. He received his B.S. in biomedical engineering from Johns Hopkins University where he played on the soccer team. He has completed fellowships under the Howard Hughes Medical Institute (neuroscience), MIT Sloan School of Management, and Harvard Business School.